Key Points
- CAS Space’s IPO highlights China’s strategic push into reusable rocket technology.
- Government support and regulatory easing are driving growth in the private space sector.
- Investors face a balance between long-term potential and significant financial and execution risks.
Comparison, examination, and analysis between investment houses
Leave your details, and an expert from our team will get back to you as soon as possible
* This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.
To read more about the full disclaimer, click here- Ronny Mor
- •
- 7 Min Read
- •
- ago 12 hours
SKN | Can Novo Nordisk’s Subscription Strategy Help It Catch Up in the Obesity Drug Race?
Novo Nordisk is rolling out a new subscription-based pricing model for its blockbuster obesity treatment Wegovy, signaling a strategic shift
- ago 12 hours
- •
- 7 Min Read
Novo Nordisk is rolling out a new subscription-based pricing model for its blockbuster obesity treatment Wegovy, signaling a strategic shift
- omer bar
- •
- 7 Min Read
- •
- ago 6 days
SKN | Is the AI Boom Expanding Beyond GPUs Into a Full Infrastructure Supercycle?
The artificial intelligence trade is entering a new phase—one that extends far beyond chips. NVIDIA’s latest results revealed a staggering
- ago 6 days
- •
- 7 Min Read
The artificial intelligence trade is entering a new phase—one that extends far beyond chips. NVIDIA’s latest results revealed a staggering
- Ronny Mor
- •
- 6 Min Read
- •
- ago 1 week
SKN | 5 Wealth Moves People Make Right After Crossing $1 Million — And What They Get Wrong
The Moment Everything Shifts Crossing the $1 million mark feels like an arrival point. In reality, it’s a transition. Until
- ago 1 week
- •
- 6 Min Read
The Moment Everything Shifts Crossing the $1 million mark feels like an arrival point. In reality, it’s a transition. Until
- omer bar
- •
- 6 Min Read
- •
- ago 2 weeks
SKN | Could J&J’s New Psoriasis Pill Disrupt the $100 Billion Biologics Market?
The approval of a new oral treatment by Johnson & Johnson marks a potentially pivotal shift in the treatment landscape
- ago 2 weeks
- •
- 6 Min Read
The approval of a new oral treatment by Johnson & Johnson marks a potentially pivotal shift in the treatment landscape